Xinda hired Liu Yongjun as group president Junshi core technical personnel Wu Hai left.

Xinda Bio today announced the appointment of Dr. Liu Yongjun, a well-known scientist in the biopharmaceutical industry, as President of the Group.
joining Xinda Bio, Liu Yongjun will be responsible for the Group's global research and development, pipeline strategy, business cooperation and international business, and report to the Group's founder, Chairman and Chief Executive Officer, Yu Dechao.
: Liu Yongjun is understood to have obtained his Ph.D. in Internal Medicine from Bethun Medical University in 1984, his Ph.D. in immunology from the University of Birmingham Medical School in 1989, and his postdoctoral program training at the university two years later.
has been deeply in the pharmaceutical industry for the next three decades: joining the multinational pharmaceutical company Shillinger, France, in 1991 as a senior scientist; Cancer Center, chair professor at Vivian Smith, chair of the Department of Immunology and founding director of the Cancer Immunology Research Center (CCIR), joined the Baylor Institute in 2011 as Chief Scientific Officer and Director of the Institute of Immunology, and in 2014 joined Mediammune, AstraZeneta's global biopharmaceutical subsidiary, as Chief Scientific Officer and Head of Global Research. Head of Sanofi Global Research from 2016 to 2020.
, Liu Yongjun has made great achievements in a number of therapeutic fields during his work.
, especially in the "tumor" and "immune" two core biopharmaceutical areas, greatly enhance drug research and development capabilities, comprehensive enrichment of early innovation pipeline.
's leadership and unique strategic thinking have also significantly improved the efficiency of first-In-Class and Best-In-Class drugs during his tenure.
In terms of scientific strength, Liu Yongjun has published more than 260 papers in leading academic journals such as Nature and Science, which have provided key drug targets in immunology and oncology, such as thymus-based lymphocytosis (TSLP), OX40 (CD134), plasma cell-like dendrobladed cells (pDC), and more, driving preclinical research in a number of fields.
, another domestic innovative pharmaceutical company recently announced personnel changes.
October 13th, Junshi Bio announced that Mr. HAIWU (Wu Hai), a director, deputy general manager and core technical staff member of the company, had applied to resign as deputy general manager of the company on the same day for personal reasons.
screenshots of the company has remained a director of the company since the announcement of Mr. HAIWU's resignation.
is responsible for the work of the company's director and deputy general manager, Mr. SHENGYAO (Yao Sheng).
, Mr. HAI WU (Wu Hai) has completed the handover of his work with Mr. SHENG YAO (Yao Sheng).
it is understood that Mr. HAI WU served as Chief Scientific Officer of Top aile, a wholly owned subsidiary of the Company, from June 2013 to December 2016, and as Deputy General Manager of the Company from March 2015 to October 2020; From March 2015 to June 2018, he served as The Company's Chief Financial Officer, as a Director of the Company from December 2016 to October 2020.
Hai WU (Wu Hai) was mainly involved in the early development of the company's JS001, JS002, JS004 and other antibody drug projects during his tenure at Junshi Bio.
the company's leading research and development personnel involved in the above-mentioned research projects and core technologies also include Feng Hui, Zhang Zhuobing, MR. SHENG YAO (Yao Sheng) three core technical personnel.
announced that at the end of 2017, the end of 2018, the end of 2019 and the end of June 30, 2020, the number of Research and Development personnel of Junshi Biological was 101 and 159, respectively. 415 and 526, accounting for 32.48 percent, 26.50 percent, 29.20 percent and 28.05 percent of the total number of employees, respectively.
same period, the number of Junshi bio-core technical personnel for 4, 4, 4 and 3 people, stable personnel, the specific personnel are as follows: screenshot self-announcement.